Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases.
Soft tissue sarcomas (STS) are a group of rare mesenchymal cancers that include approximately 50 histological types and account for 1% of all adult cancers. The standard curative treatment option for localized disease is surgical resection and, if a surgically removed tumor exhibits high-risk characteristics, adjuvant chemotherapy and radiotherapy may be administered. Sarcoma presenting at an advanced stage has a dismal prognosis and survival has not markedly improved over the last 20 years. The standard first-line treatment for advanced STS, other than gastrointestinal stromal tumors, is cytotoxic chemotherapy. Therapies targeting pro-angiogenic factors have been a focus of drug development for STS over the last few years. Pazopanib, a multitargeted tyrosine kinase inhibitor, is a novel treatment option for patients with metastatic STS in the second-line setting. This is a presentation of 2 case reports of patients with metastatic STS who responded well to treatment with pazopanib.
['Sedef|Ali Murat|AM|', 'Köse|Fatih|F|', 'Doğan|Özlem|Ö|', 'Ergün|Tarkan|T|', 'Sezer|Ahmet|A|', 'Mertsoylu|Hüseyin|H|', 'Muallaoğlu|Sadik|S|', 'Beşen|Ayberk|A|', 'Özyilkan|Özgur|Ö|']
pazopanib metastatic soft tissue sarcomas response rate targeted therapy